Literature DB >> 15953991

Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.

T Suuronen1, T Nuutinen, J Huuskonen, J Ojala, A Thornell, A Salminen.   

Abstract

OBJECTIVE: Our aim was to study how different SERMs modulate the inflammatory responses induced by lipopolysaccharide (LPS) or unmethylated CpG-oligonucleotides in mouse and rat microglial cells.
MATERIALS AND METHODS: Inflammatory responses of mouse N9 microglial cells and rat primary hippocampal microglia to lipopolysaccharide (LPS) exposure were recorded by the secretion of nitric oxide (NO) and cytokine IL-6 in two models where SERM was added either 24 h before LPS addition or simultaneously or even after the LPS exposure. The responses of 17beta-estradiol, tamoxifen, raloxifene and ICI 182.780 were compared. Responses were recorded by ELISA, Northern and EMSA assays.
RESULTS: SERMs but not 17beta-estradiol induced a significant, concentration-dependent anti-inflammatory response both in rat primary microglial cells and in mouse N9 microglial cells. The response was observed both in NO and IL-6 secretion as well as in total IL-6 mRNA expression. We have recently observed that histone deacetylase (HDAC) inhibitors can potentiate the LPS-induced inflammatory response. Raloxifene and tamoxifen inhibited the potentiation of LPS response induced by trichostatin A, an HDAC inhibitor, in N9 microglia. A SERM-induced anti-inflammatory response was observed in acute models where SERM was added simultaneously or even up to 6 h later than LPS exposure. In contrast, the pretreatment of N9 microglia with tamoxifen or raloxifene for 30 h before LPS exposure did not provide any protection against the LPS response. We also observed that the raloxifene-induced protection in N9 microglia was connected to a decline of LPS-induced DNA binding activity of AP-1 but not that of NF-kappaB transcription factors.
CONCLUSIONS: Our results show that tamoxifen, raloxifene and ICI 182.780 induce an anti-inflammatory response in acute models of mouse and rat microglial cells. It seems that this response is not estrogen receptor-mediated but, probably, is attributable to some SERM-induced modulation of LPS-activated pro-inflammatory signalling cascades.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953991     DOI: 10.1007/s00011-005-1343-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  26 in total

1.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 2.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  Dietary inflammation factor rating system and risk of Alzheimer disease in elders.

Authors:  Yian Gu; Jeri W Nieves; Jose A Luchsinger; Nikolaos Scarmeas
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

Review 4.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

Review 5.  Gene regulation and genetics in neurochemistry, past to future.

Authors:  Steven W Barger
Journal:  J Neurochem       Date:  2016-10-17       Impact factor: 5.372

6.  Age-related changes in neuroprotection: is estrogen pro-inflammatory for the reproductive senescent brain?

Authors:  Farida Sohrabji; Shameena Bake
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 7.  The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.

Authors:  Giuseppe Faraco; Leonardo Cavone; Alberto Chiarugi
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

Review 8.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

9.  Neuroprotective actions of selective estrogen receptor modulators.

Authors:  Lydia L DonCarlos; Iñigo Azcoitia; Luis M Garcia-Segura
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

Review 10.  Molecular bases of methamphetamine-induced neurodegeneration.

Authors:  Jean Lud Cadet; Irina N Krasnova
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.